Clinical course and need for hospital admission after lithium discontinuation in patients with bipolar disorder type I or II: mirror-image study based on the LiSIE retrospective cohort

Louise Öhlund, Michael Ott, Malin Bergqvist, Sofia Oja, Robert Lundqvist, Mikael Sandlund, Ellinor Salander Renberg and Ursula Werneke

Background
Currently, the evidence for lithium as a maintenance treatment for bipolar disorder type II (BD-II) remains limited. Guidelines commonly extrapolate recommendations for BD-II from available evidence for bipolar disorder type I (BD-I). Comparing the impact of lithium discontinuation is one way of assessing effectiveness in both groups.

Aims
To compare the impact of lithium discontinuation on hospital admissions and self-harm in patients with BD-I or schizoaffective disorder (SZD) and patients with BD-II or other bipolar disorder.

Method
Mirror-image study, examining hospital admissions within 2 years before and after lithium discontinuation in both patient groups. This study was part of a retrospective cohort study (LiSIE) into effects and side-effects of lithium for maintenance treatment of bipolar disorder as compared with other mood stabilisers.

Results
For the whole sample, the mean number of admissions/patient/review period doubled from 0.44 to 0.95 (P<0.001) after lithium discontinuation. The mean number of bed days/patient/review period doubled from 11 to 22 (P = 0.025). This increase in admissions and bed days was exclusively attributable to patients with BD-I/SZD. Not having consulted with a doctor prior to lithium discontinuation or no treatment with an alternative mood stabiliser at the time of lithium discontinuation led to more admissions.

Conclusions
The higher relapse risk in patients with BD-I/SZD suggests a higher threshold for discontinuing lithium than for patients with BD-II/other bipolar disorder. In patients with BD-II/other bipolar disorder, however, judged on the impact of discontinuation alone, lithium did not appear to prevent more severe depressive episodes requiring hospital admission.

Declaration of interest
M.O. has been a scientific advisory board member of Astra Zeneca, Sweden, 2018. U.W. has received funding for educational activities on behalf of Norrbotten Region (Masterclass Psychiatry Programme 2014–2018 and EAPM 2016, Luleå, Sweden) from: Astra Zeneca, Eli Lilly, Janssen, Novartis, Otsuka/Lundbeck, Servier, Shire and Sunovion.

Keywords
Bipolar disorder; lithium; mood stabiliser; admission; hospitalisation.

Copyright and usage
© The Author(s) 2019. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Participants
For LiSIE, we identified all patients in the Swedish region of Norrbotten, at least 18 years of age and who, according to ICD-10, had been diagnosed with bipolar disorder (F31) or SZD (F25) or who had been prescribed lithium as a mood stabiliser. Patients were eligible when they had received a diagnosis of bipolar disorder or SZD on at least two occasions, at least 6 months apart any time between 1997 and 2011. We retrospectively examined routine clinical data recorded until 31 December 2015 and performed the data extraction and validation in 2016 and 2017. The data was analysed in 2018.

Patients were potentially eligible for inclusion into this study when we found a lithium prescription discontinued according to the electronic prescription database. We included all patients, who (a) had discontinued lithium at any time between 1997 and 2013 for more than 7 days with the intention of stopping for good as indicated by the medical records, (b) had continuously received lithium for at least 2 years before stopping lithium, and (c) were available for follow-up for 2 years after stopping lithium. Some patients had discontinued lithium on several occasions. For the purpose of this study, we only considered the first episode of discontinuation preceded by 2 years of continuous lithium treatment. To achieve a perfect mirror, we excluded all patients whose review periods fell short of 2 years post-lithium discontinuation.

Variable definitions and outcomes
The index event for our mirror-image study was lithium discontinuation. The pre- and post-mirror-image review periods, were both set to 2 years. We systematically abstracted the case records for each patient to obtain information regarding (a) baseline characteristics including diagnosis, (b) date of lithium discontinuation, and (c) length of lithium treatment before discontinuation. As outcomes, within 2 years before and after lithium discontinuation, we recorded hospital utilisation in terms of (a) number and type of hospital admissions, (b) type of affective episode at admission, and (c) bed days in hospital. When lithium was discontinued during an admission, we counted that admission in the pre-mirror period. We also compared the frequency of documented self-harm events before and after stopping lithium. All events of self-harm or suicide attempts, where a patient had received psychiatric, medical or surgical care in connection with the event, were recorded.

Diagnosis
In the medical records, clinicians had used diagnoses either according to DSM or ICD in their various editions. To establish the diagnoses used for our analysis, we considered diagnoses recorded in the medical records at four time points, (a) time of lithium start, (b) before lithium discontinuation, (c) at the end of the 2 years follow-up period after lithium discontinuation, and (d) last diagnosis before the end of our review period. From the four individual diagnoses, we then created a summary diagnosis as an approximation of what most likely the lifetime diagnosis would be according to DSM-5.14 We divided diagnoses into two categories, (a) BD-I/SZD and (b) BD-II/other bipolar disorder. The presence of a manic episode precluded patients from being allocated to the second group. In the category ‘other bipolar disorder’, we included patients with an explicitly recorded diagnosis of bipolar disorder, who (a) had not been given a diagnosis of BD-II and (b) had not experienced any manic episode (which would have lifted them into the BD-I category). This category included patients with a recorded diagnosis of BD not further specified and patients for whom the clinicians specified that a hypomanic episode had only appeared after taking antidepressant medication. We also checked whether patients ever had mixed features in a mood-disorder episode (mixed features) or rapid cycling. The final diagnoses were validated by at least two researchers (LO, MB, SO, UW).

Lithium exposure
Patients with lithium prescriptions in the LiSIE cohort had to have at least two lithium serum concentrations >0.2 mmol/L recorded in the laboratory database to count as truly exposed. For this particular study, patients needed to have been treated with lithium for at least 2 years before stopping lithium. There was no minimum requirement for a lithium serum concentration. Instead, we adjusted for mean lithium serum concentration in the 2-year period before lithium discontinuation in our multiple linear regression analysis. We also confirmed the starting point of lithium treatment as documented in the medical records, going back as far as 1967.

Lithium discontinuation
We included all episodes for which the medical records indicated that lithium was discontinued with the intention to stop for good. Since lithium discontinuation could precede cancellation of the prescription, we confirmed from the medical records the point of time of lithium discontinuation as accurately as possible. We distinguished between rapid discontinuation, within 0 and 14 days, and gradual discontinuation, where lithium was tapered over more than 14 days. We also checked the records for the reasons for lithium discontinuation and if patients had consulted a doctor before.

Mood stabilising treatment at the point of lithium discontinuation and during the post-mirror period
We also compared mood stabiliser treatment after lithium discontinuation as a potential major confounder for our outcomes. We checked the medical notes for use of alternative mood stabilisers – olanzapine, quetiapine, aripiprazole, risperidone, valproate, lamotrigine, carbamazepine and topiramate – at the point of lithium discontinuation, at 3 months and 2 years after lithium discontinuation. We defined alternative mood stabiliser treatment as stable by proxy of having been treated with the same mood stabiliser at 3 months and 2 years after lithium discontinuation. We also checked for lithium reinstatement.

Alcohol and/or substance use disorder
We screened the medical notes for alcohol and/or substance use disorder within 2 years before and after lithium discontinuation. Alcohol and/or substance use disorder was recorded when (a) there was an explicit diagnosis according to DSM or ICD in their various editions, or (b) when there was an explicit reference in the medical notes.

Control for bias
Of all patients approached, 75% consented to inclusion in the LiSIE study. In accordance with the ethical approval granted, we controlled for selection bias, comparing age, gender, maximum recorded serum lithium and creatinine levels as key parameters, available in anonymised form. We did not find any significant difference between participating and non-participating patients. To minimise observer and recording bias, all data was abstracted by two separate reviewers.

Statistical analysis
We conducted a descriptive analysis, establishing the frequency of all variables in our database. Means and standard deviations were
calculated for continuous data. Frequencies and percentages were calculated for categorical data. We then stratified further according to type of bipolar disorder. For group comparisons of continuous variables, we used paired t-test when group sizes were sufficiently large (≥40 in either group) as this test is fairly robust against violations of the normal distribution assumption. 15 For smaller group sizes, we used Wilcoxon signed rank test. For categorical variables, we used McNemar’s and Pearson’s χ²-tests.

We conducted multiple linear regression analyses in order to adjust for possible confounders in the analysis of the association between the change in hospital admissions and bed days and diagnostic group, BD-I/SZD versus BD-II/other bipolar disorder. We created three models with the following outcomes (a) change in total number of admissions, (b) change in number of compulsory admissions only, and (c) change in number of bed days. We tested for factors identified in the published literature9,13,16,17 age, mixed status, lithium concentration, mood stabiliser treatment at lithium discontinuation, post-mirror stable mood stabiliser treatment, rapid or gradual withdrawal, consulted with a doctor before discontinuing, alcohol and/or substance use disorder. Effects were reported as estimated marginal means, which give the mean increase in unit of outcome, number of admissions or bed days, according to factors under study.

Kaplan–Meier plots were used to map the time periods from stopping lithium to first admission after lithium discontinuation. To account for type of bipolar disorder and speed of lithium discontinuation, we created four separate survival functions, comparing (a) BD-I/SZD versus BD-II/other bipolar disorder, (b) rapid versus gradual lithium discontinuation for the whole group, (c) rapid versus gradual lithium discontinuation for patients with BD-I/SZD only and (d) rapid versus gradual lithium discontinuation for patients with BD-II/other bipolar disorder only. We tested potential differences between groups using the log rank test. Throughout, the statistical significance level was set to P<0.05. The statistical analysis was conducted with IBM SPSS Statistics version 25.

Results

Participant characteristics

Of 1564 eligible patients, 871 (56%) had been treated with lithium during the study period. There were 467 (54%) patients who discontinued lithium on at least one occasion with the intention of stopping for good. In total, 194 patients met the inclusion criteria (Fig. 1); their baseline characteristics are described in Table 1. The mean lithium concentration over the 2 years before lithium discontinuation was 0.61 (s.d. = 0.19) mmol/L, based on 1734 individual measurements in the whole sample (Table 1).

Treatment with mood stabilisers at the point of lithium discontinuation and during the post-mirror period

At the point of lithium discontinuation, 36% of patients with BD-I/SZD and 38% of patients with BD-II/other bipolar disorder received alternative mood stabiliser treatment (P = 0.741) (Table 1). Three months after lithium discontinuation, 50% of patients with BD-I/SZD and 38% of patients with BD-II/other bipolar disorder were treated with an alternative mood stabiliser (P = 0.101). Two years after lithium discontinuation, 51% of patients with BD-I/SZD and 46% of patients with BD-II/other bipolar disorder were treated with an alternative mood stabiliser (P = 0.464). During the post-mirror period, 35% of patients with BD-I/SZD and 32% of patients with BD-II/other bipolar disorder were considered to have a stable treatment with an alternative mood stabiliser (P = 0.649). In total, 31% of patients reinstated lithium at some point during the post-mirror period. Patients with BD-I/SZD restarted their lithium treatment significantly more often than patients with BD-II/other bipolar disorder (P = 0.003) (Table 1).

Change in number of admissions within 2 years before and after lithium discontinuation

In the whole sample, 37 patients had 86 admissions before, and 79 patients had 185 admissions after lithium discontinuation. The number of admissions increased for about 33% of patients and decreased for 10%. For 57%, there was no change. The mean number of admissions/patient/review period increased significantly (P<0.001). The number of compulsory admissions increased for 13% of patients and decreased for 2% after lithium discontinuation. For 85%, there was no change. The mean number of compulsory admissions/patient/review period also increased significantly (P<0.001). There were significantly more admissions for all types of episodes after lithium discontinuation, including mood episodes with mixed features (Table 2).

Change in number of admissions according to type of disorder

For patients with BD-I/SZD, the number of admissions increased for 50% of patients and decreased for 7%. For 43%, there was no change. The number of admissions increased from 33 to 130. The mean number of admissions/patient/review period increased significantly (P<0.001) (Table 2). Further analysis showed that this increase was irrespective of whether patients ever had experienced mixed features or not (P<0.001 for both). There were significantly more admissions for both manic (P<0.001) and depressive episodes (P = 0.009). For patients with BD-I/SZD, the number of admissions increased significantly, irrespective of whether lithium was reinstated (P<0.001 or not) (P = 0.009).

For patients with BD-II/other bipolar disorder, the number of admissions increased for 16% of patients and decreased for 13%. For 71%, there was no change. The number of admissions increased from 53 to 55. The mean number of admissions/patient/review period did not change significantly after lithium discontinuation, regardless of reason for admission (Table 2). Neither did this number change for patients with mixed or without mixed features ever (P = 0.863 and P = 0.545, respectively). For patients with BD-II/other bipolar disorder, there was no significant change in number of admissions, irrespective of whether lithium was reinstated (P = 0.667) or not (P = 0.669).

For patients with BD-I/SZD, the multiple linear regression model showed that the mean number of admissions after lithium discontinuation was significantly higher compared with BD-II/other bipolar disorder (P<0.001). Not having consulted with a doctor prior to lithium discontinuation (P = 0.032) was another factor associated with significantly more admissions after lithium discontinuation. However, being treated with an alternative mood stabiliser at the time of lithium discontinuation was associated with significantly fewer admissions (P = 0.012) (Table 3). The mean number of compulsory admissions in patients with BD-I/SZD, compared with BD-II/other bipolar disorder, was also higher (0.38, 95% CI 0.18–0.57, P<0.001). Having consulted with a doctor prior to lithium discontinuation was associated with fewer compulsory admissions after lithium discontinuation (–0.29, 95% CI –0.50 to –0.08, P = 0.007). In this model, being treated with an alternative mood stabiliser at the time of lithium discontinuation was not statistically significant (–0.12, 95% CI –0.36 to 0.11, P = 0.308) (data not shown in detail).
Change in number of bed days within 2 years before and after lithium discontinuation

In the whole sample, the number of bed days increased for 33% of patients and decreased for 13%. For 54%, there was no change. The total number of bed days increased from 2218 to 4240 after lithium discontinuation. Mean number of bed days/patient/review period increased significantly ($P = 0.025$) (Table 2).

Change in number of bed days according to type of disorder

For patients with BD-I/SZD, the number of bed days increased for 49% of patients and decreased for 12%. For 39%, there was no change. The number of bed days increased from 1018 to 3196. Mean number of bed days/patient/review period increased significantly ($P = 0.005$) (Table 2). Further analysis showed that this increase was irrespective of whether patients ever had experienced mixed features or not ($P = 0.001$ and $P = 0.024$). For patients with BD-I/SZD who reinstated lithium, the number of bed days increased significantly ($P<0.001$). For those who did not reinstate lithium, there was no change ($P = 0.209$).

For patients with BD-II/other bipolar disorder, the number of bed days increased for 16% of patients and decreased for 14%. For 70%, there was no change. The number of bed days decreased from 1200 to 1044. For patients with BD-II/other bipolar disorder, mean number of bed days did not change significantly after lithium discontinuation ($P = 0.733$) (Table 2). Neither did this number change for patients with or without mixed features ever ($P = 0.575$ and $P = 0.444$, respectively). For patients with BD-II/other bipolar disorder, there was no significant change in number of bed days, irrespective of whether lithium was reinstated ($P = 0.767$) or not ($P = 0.920$).

The multiple linear regression model showed that after lithium discontinuation, compared with BD-II/other bipolar disorder, the
mean number of bed days was significantly higher for patients with BD-I/SZD ($P = 0.015$). In this model, not having consulted with a doctor prior to lithium discontinuation ($P = 0.067$) and being treated with an alternative mood stabiliser at the time of lithium discontinuation was not statistically significant ($P = 0.133$) (Table 3).

### Rapid or gradual discontinuation of lithium

In the whole sample, 70% of patients were ‘rapid discontinuers’. Gradual lithium withdrawal was significantly more common among patients with BD-II/other bipolar disorder compared with patients with BD-I/SZD ($P = 0.048$) (Table 1). In the group of rapid discontinuers, significantly fewer patients consulted with a doctor before stopping lithium ($P < 0.001$). At the time of lithium discontinuation, treatment with other mood stabilisers did not differ significantly between rapid and gradual discontinuers ($P = 0.079$). The adjusted regression model showed no significant difference in number of hospital admissions or bed days in relation to the speed of lithium discontinuation (Table 3).

The Kaplan–Meier plots, which mapped the time periods from lithium discontinuation to first admission for different subgroups, are shown in Fig. 2. The mean ‘survival’ time to first admission after lithium discontinuation was 14 months (95% CI 11.7–15.7) for patients with BD-I/SZD and 20 months (95% CI 18.3–21.5) for patients with BD-II/other. There was a significant difference between both survival curves ($P < 0.001$), indicating a worse course for patients with BD-I/SZD (Fig. 2(a)). The survival curves did not show any significant difference between rapid or gradual discontinuers, neither for the whole sample ($P = 0.079$) (Fig. 2b), nor for BD-I/SZD ($P = 0.240$) (Fig. 2c), nor for patients with BD-II/other bipolar disorder ($P = 0.597$) (Fig. 2d).

### Self-harm after lithium discontinuation

In the pre-mirror period, six patients had eight episodes of self-harm. In the post-mirror period, 12 patients had 18 episodes of self-harm. This did not constitute a significant change ($P = 0.180$). Neither were there significantly more episodes of self-harm per patient ($P = 0.069$). However, men ($P = 0.046$) but not women ($P = 0.249$) had significantly more episodes of self-harm after lithium discontinuation. Regarding diagnostic subgroups, only patients with BD-I/SZD who had ever experienced mixed features had significantly more episodes of self-harm ($P = 0.034$) after lithium discontinuation.

### Discussion

#### Main findings

To our knowledge, this is the first study examining the effects of lithium discontinuation for different subtypes of bipolar disorder...
Öhlund et al. found that our findings might not be considered surprising. But as patients acted as their own controls, illness severity should not affect the results. We found a huge effect size for BD-I/SZD but no significant effect for BD-II/other bipolar disorder. In any event, in terms of suicidal attempts, BD-II seems to be an equally severe condition as BD-I.18,19 BD-II may even be more severe in terms of chronicity, impairment from depressive symptoms and subthreshold symptoms.18 This was also observed in our study.

### Comparison with other studies

Proportion of patients discontinuing lithium

In our study, 54% of patients discontinued lithium during our observation period. This is in line with other studies; medication non-adherence rates of 50% have been reported for patients with bipolar disorder.20 For lithium, reported non-adherence rates have varied widely, from 6%21 to 58%.22 Adherence estimates depend on a variety of factors, including length of the observation period, patient population sampled and prospective or retrospective study design. The means by which non-adherence is measured are also important: prescription counts, medicine possession ratios, patient self-reports, physician estimates or lithium concentrations may all yield different results.23,24

### Rapid or gradual lithium discontinuation

Previous studies have shown that gradual instead of rapid discontinuation can reduce manic and depressive relapses and even suicidal risk. Interestingly, the advantages of gradual discontinuation were greater in BD-II than BD-I, both in terms of longer time until first relapse.
and longer periods of stability.\textsuperscript{16,17} After lithium discontinuation, relapse into mania tends to occur sooner than relapse into depression and can be delayed by gradual discontinuation.\textsuperscript{18,19} In our study, speed of lithium discontinuation was not significantly associated with change in the number of admissions or bed days. However, not having consulted with a doctor was associated with an increase in numbers of admissions. Being treated with an alternative mood stabiliser at time of lithium discontinuation also protected against readmission. This highlights the importance of continued regular contact with patients using lithium maintenance therapy and continued engagement after lithium discontinuation.\textsuperscript{11} However, as pointed out above, the rate of lithium discontinuation might not have affected the number of future admissions, but rather the time to first admission after lithium discontinuation.\textsuperscript{16} In our study, survival curves did not show any significant difference between rapid or gradual discontinuers, neither for the whole group, nor for the BD-I/SZD and BD-II/other bipolar disorder subgroups.

**Lithium as a maintenance treatment for BD-II**

Several large cohort and register studies have shown the superiority of lithium for the treatment of bipolar disorder. However, most have not distinguished between the different types.\textsuperscript{2,4,6,26,27} Subtypes of bipolar disorder may not be part of the register data informing large cohort studies.\textsuperscript{7} Misclassification can become a problem if different diagnostic systems or different versions of the same diagnostic system have been used. In 2018, based on a systematic review of naturalistic observational studies, Kessing et al suggested the superiority of lithium in real-life settings.\textsuperscript{8} Of 11 studies included, only two stratified their results according to BD-I or BD-II.\textsuperscript{28,29} One of these suggested that patients with BD-II were more likely to be lithium responders than patients with BD-I.\textsuperscript{29} The other one concluded that lithium had some advantage compared with other stabilising treatment in both BD-I and BD-II.\textsuperscript{30} A further study, not included in that systematic review, found that 'affective morbidity, as reflected in the portion of time ill during lithium treatment, was significantly lower in BD-II than BD-I'.\textsuperscript{31} Our own study of reasons for discontinuation of lithium treatment in 468 patients showed that patients with BD-II/other bipolar disorder more often stopped lithium as a result of a perceived lack of effect. Time on lithium was also significantly shorter.\textsuperscript{13} Soares-Weiser et al conducted an extensive systematic review and meta-analysis of randomised controlled or quasi-randomised controlled trials on the effectiveness of various mood stabilisers. They suggested that lithium might be less effective for BD-II, but ultimately the evidence was too weak to arrive at a firm conclusion.\textsuperscript{32} Another recently updated meta-analysis of randomised controlled studies explored relapse prevention in patients with bipolar disorder, comparing lithium against placebo and anticonvulsants.\textsuperscript{33,34} Lithium was more effective than placebo for the prevention of overall mood and manic episodes. Lithium was also more effective than anticonvulsants for the prevention of manic, but not of overall mood or depressive episodes. Fourteen studies were included. However, only two trials explicitly concerned patients with BD-II.\textsuperscript{35,36} Two further studies included a fraction of patients with BD-II\textsuperscript{37} and bipolar disorder not otherwise specified.\textsuperscript{38} Therefore, the results of this meta-analysis are mainly applicable to BD-I. Two more recent trials compared lithium with antidepressants in patients with BD-II. In both trials, there was no difference in relapse rate.\textsuperscript{39,40} Yet, concerns remain that antidepressants, unopposed by mood stabilisers, increase the risk of manic episodes.\textsuperscript{41,42} In view of the sparse evidence, treatment recommendations for BD-II mainly reflect findings from BD-I studies. Most

---

**Table 3  Factors associated with changes in the number of admissions and bed days after lithium discontinuation**

| Parameter                                      | Admissions Mean difference\textsuperscript{a} | 95% CI Lower | 95% CI Upper | P      | Bed days Mean difference\textsuperscript{a} | 95% CI Lower | 95% CI Upper | P      |
|------------------------------------------------|-----------------------------------------------|-------------|-------------|-------|-----------------------------------------------|-------------|-------------|-------|
| Gender                                         |                                               |             |             |       |                                               |             |             |       |
| Men                                            | -0.122                                        | -0.637      | 0.392       | 0.639 | -3.234                                        | -33.675     | 16.208      | 0.743 |
| Women (baseline)                               |                                               |             |             |       |                                               |             |             |       |
| Type of disorder                               |                                               |             |             |       |                                               |             |             |       |
| BD-I/SZD                                       | 1.011                                         | 0.502       | 1.520       | <0.001| 23.946                                        | 4.707       | 43.184      | 0.015 |
| BD-II/other bipolar disorder (baseline)        |                                               |             |             |       |                                               |             |             |       |
| Age at lithium discontinuation, mean           |                                               |             |             |       |                                               |             |             |       |
| Yes                                            | 0.123                                         | -0.426      | 0.673       | 0.658 | 18.717                                        | -2.692      | 39.485      | 0.077 |
| No (baseline)                                  |                                               |             |             |       |                                               |             |             |       |
| Mixed episode ever                             |                                               |             |             |       |                                               |             |             |       |
| Yes                                            | 0.123                                         | -0.426      | 0.673       | 0.658 | 18.717                                        | -2.692      | 39.485      | 0.077 |
| No (baseline)                                  |                                               |             |             |       |                                               |             |             |       |
| Lithium concentration (mmol/L) within 2 years before lithium discontinuation | 0.892 | -0.432 | 2.216 | 0.185 | 1.794 | -48.281 | 51.870 | 0.944 |
| Other mood stabiliser at the time of lithium discontinuation | Yes | -0.804 | -1.433 | -1.176 | 0.012 | -18.178 | -41.953 | 5.597 | 0.133 |
| No (baseline)                                  |                                               |             |             |       |                                               |             |             |       |
| Stable treatment with an alternative mood stabiliser during post-mirror period | Yes | 0.321 | -0.330 | 0.972 | 0.332 | -4.056 | -28.668 | 20.556 | 0.745 |
| No (baseline)                                  |                                               |             |             |       |                                               |             |             |       |
| Speed of withdrawal                            |                                               |             |             |       |                                               |             |             |       |
| Gradual, >14 days                              | 0.267                                         | -0.291      | 0.824       | 0.346 | 13.436                                        | -7.635      | 34.506      | 0.210 |
| Rapid, ≤14 days (baseline)                     |                                               |             |             |       |                                               |             |             |       |
| Patient consulted doctor before lithium discontinuation | Yes | -0.615 | -1.175 | -0.054 | 0.032 | -19.780 | -40.963 | 1.403 | 0.067 |
| No (baseline)                                  |                                               |             |             |       |                                               |             |             |       |
| Substance/alcohol use disorder within 2 years after lithium discontinuation | Yes | 0.696 | -0.197 | 1.589 | 0.126 | 14.811 | -18.951 | 48.573 | 0.388 |
| No (baseline)                                  |                                               |             |             |       |                                               |             |             |       |

\textsuperscript{a} Of estimated marginal means.

BD-I, bipolar disorder type I; SZD, schizoaffective disorder; BD-II, bipolar disorder type II; other bipolar disorder, unspecified bipolar disorder or subgroup specified otherwise.
guidelines also stress the importance of taking the predominant polarity into account.\textsuperscript{9-11} Only the Canadian guideline distinguishes clearly between BD-I and BD-II, recommending quetiapine, lithium or lamotrigine as first-line agents for the maintenance treatment of BD-II disorder.\textsuperscript{42}

Lithium as a treatment for bipolar disorder with mixed features

At present, the impact of mixed features on treatment outcomes of bipolar disorder is only poorly understood.\textsuperscript{9} Most maintenance treatment trials concern mixed features in the context of BD-I but not BD-II.\textsuperscript{44} Guidelines tend to agree that antidepressants should not be used in mixed states.\textsuperscript{1,9,10,41,42} Evidence concerning mood stabilisers as maintenance therapies for patients with mixed features is still virtually absent.\textsuperscript{12}

Lithium for the prevention of suicide and self-harm in patients with BD-II and mixed states

It has been suggested that the risk of suicide in BD-II is higher than in BD-I. The reasons for this are not quite clear. A higher occurrence of agitated depression and anxiety may play a role.\textsuperscript{49} A Finnish cohort study monitored the incidence of suicide attempts in 177 patients with bipolar disorder for 5 years. In this study, type of bipolar disorder did not emerge as a predictor of suicide attempts. The highest incidence of suicide attempts was seen during mixed states.\textsuperscript{46} In another study of 3099 out-patients with major depressive disorder or bipolar disorder, mixed features also increased the risk of suicidal acts.\textsuperscript{67} Yet, a third study of 290 patients with bipolar disorder found that depressive symptoms carried an increased risk of suicidal ideation but mixed symptoms did not contribute additionally.\textsuperscript{68}

Few studies have explicitly explored the role of lithium in the prevention of suicide and self-harm in patients with BD-II and mixed states. A recent meta-analysis found a substantial risk reduction of suicide and suicide attempts among patients with bipolar disorder overall during long-term lithium treatment.\textsuperscript{69} As suicide and suicide attempts are relatively rare events, it is difficult to power trials sufficiently to examine these outcomes. This makes it even more difficult to stratify by type of bipolar disorder. In an 8-year prospective Swedish register study of 50 000 patients, lithium significantly reduced suicide-related events for patients with BD-II, but not with BD-I or mixed bipolar disorder.\textsuperscript{5} In our study, patients with BD-I/SZD with mixed features had significantly more episodes of self-harm after lithium discontinuation.

**Strengths**

The mirror-image design allowed us to conduct a quasi-experimental observational study with lithium discontinuation as the intervention. The pre/post design allowed individuals acting as their own controls, thereby minimising confounding at an individual level.\textsuperscript{50,51} Our study was not based on register data but real-life detailed clinical data at symptom and treatment level going back as far as 1967. In most randomised controlled trials, retention in a 2-year study may not exceed 10%.\textsuperscript{7} In our study, of all the patients

---

**Fig. 2** "Survival" time to first psychiatric hospital admission within 2 years after lithium discontinuation.

(a) Probability of admission at time $t$ or later, stratified by type of subgroup; (b) probability of admission at time $t$ or later, stratified by speed of withdrawal; (c) probability of admission at time $t$ or later, stratified by bipolar disorder (BD-I)/schizoaffective disorder (SZD) and speed of withdrawal; (d) probability of admission at time $t$ or later, stratified by BD-II/other bipolar disorder and speed of withdrawal.
who received lithium for at least 2 years prior to discontinuation, 90% were also available for follow-up for 2 years after discontinuation. A further strength was the high rate of consent for participation into the study. Age and gender distribution of consenting and non-consenting patients was similar. Therefore, the likelihood of selection bias is low. We could validate the diagnoses from the case records. This allowed distinction between the various types of bipolar disorder, adjustment for mixed features and exclusion of other diagnoses including schizophrenia. We established lithium treatment status, not only by prescription but also by lithium serum concentrations. Access to the medical records allowed us to determine the time point of lithium discontinuation much more accurately. Our main outcomes, number of hospital admissions and bed days, were easily verifiable in the medical records. For the detection of self-harm episodes, integrated records from the other specialist services within the region were available for review.

Limitations
Our study had a retrospective observational design using patients as their own controls. We did not compare patients who discontinued lithium with a ‘true’ control group of patients who remained on lithium. The non-randomised design limited our ability to make direct comparisons between lithium and other mood stabilisers. As in other studies, women had higher rates of BD-II in our study. But this is unlikely to have influenced our findings. Within the two diagnostic groups, there were no gender differences concerning hospital utilisation. Besides, men and women tend to respond similarly to lithium.

For this particular study, we did not require any minimum serum concentration for the 2 years before lithium discontinuation. The mean lithium concentration turned out to be ≥0.6 mmol/L in 54% and ≥0.4 mmol/L in 88% of patients. Thus, the results would have been unlikely to differ if we had employed a specific lithium cut-off point. In our multiple linear regression analysis, lithium concentration was not significantly associated with a change in number of admissions or bed days.

The quality of our data depended on the quality of the information in the medical notes. This also held true for the recording of diagnosis and type of mixed features. But as we had access to data at symptom level, we judge the potential for misclassification to be less than in other observational studies based on register data. The mirror-image design minimised confounding at an individual level. However, there might have been other changes during the post-mirror period. For example, patients who discontinued lithium could also have stopped all other medications. Therefore, we checked treatment with mood stabilisers at the point of lithium discontinuation and in the post-mirror period.

The retrospective observational study design did not allow us to detect changes in mental status or functioning in daily life that did not lead to admission. Admission to hospital as the primary outcome criterion means that mild to moderately severe episodes will most likely be missed completely. This holds especially true for individuals with BD-II; hypomanic episodes rarely result in hospital admission. In some countries such as the USA, an admission to hospital may by definition change the diagnosis from hypomania to mania. Thus, for patients with BD-II, the pre-post lithium discontinuation design only makes it possible to compare hospital admission rates for depressions. But depressive episodes tend to affect quality of life much more than hypomanic episodes. Therefore, we consider the criterion of admissions/readmissions a valid outcome parameter, which has also been used in many other studies.

As we did not find an effect of lithium discontinuation for patients with BD-II/other bipolar disorder, the question arises whether our study was underpowered. However, there was a significant change in the number of admissions and bed days for patients with BD-I/SZD. As the sample sizes for both BD-I/SZD and BD-II/other bipolar disorder were similar we would not expect the sample sizes to be insufficient in either case. Yet, the sample sizes in our study were insufficient to assess suicide as an outcome. Neither were the sample sizes sufficient to explore further factors associated with self-harm after lithium discontinuation. For the same reason, a more detailed examination of polarity of first admission after lithium discontinuation and subsequent lithium reinstatement were factors beyond the scope of this mirror-image study. We intend to take this up in future work based on the LiSIE study.

Implications for practice
Lithium discontinuation in patients with BD-I/SZD comes at a cost of deteriorated mental health and increased hospital utilisation. In this group, risk of self-harm may particularly increase in men and patients with mixed features. In patients with BD-II/other bipolar disorder, judged on the impact of discontinuation alone, lithium did not appear to prevent more severe depressive episodes requiring hospital admissions. The role of lithium in the treatment of BD-II and prevention of suicide and self-harm irrespective of BD type requires further investigation. The higher relapse risk in patients with BD-I/SZD points towards a need to apply a higher threshold for lithium discontinuation for this group than for patients with BD-II/other bipolar disorder. Ultimately though, the decision to stop lithium has to be individualised for each patient. Our findings identify a need for more clinical research to enable treatment guidelines to distinguish the various types of bipolar disorder.

Louise Öhlin, MD, Research Registrar, Sunderby Research Unit – Psychiatry, Department of Clinical Sciences, Umeå University, Sweden; Michael Ott, MD, Consultant Physician, Department of Public Health and Clinical Medicine – Medicine, Umeå University, Sweden; Malin Bergqvist, MD, Consultant Psychiatrist, Piteå Alviks Hospital, Department of Psychiatry, Sweden; Sofia Oja, MD, Consultant Psychiatrist, Institute of Psychiatric Research, Umeå University, Sweden; Robert Lundqvist, MD, Consultant Psychiatrist, Sunderby Hospital, Sweden; Mikael Sandlund, MD, PhD, Professor of Psychiatry, Department of Clinical Sciences – Psychiatry, Umeå University, Sweden; Ellinor Salander Renberg, PhD, Professor of Psychiatry, Department of Clinical Sciences – Psychiatry, Umeå University, Sweden; Ursula Werneke, MD, MSc, PhD, Department of Clinical Sciences – Psychiatry, Sunderby Hospital, both Norrbotten Region, Sweden.

Correspondence: Ursula Werneke. Email: uwernerke@gmail.com

First received 11 May 2019, final revision 14 Oct 2019, accepted 16 Oct 2019

Funding
This work was supported by a grant of the Research & Development Fund, Research and Innovation Unit, and the Department of Psychiatry Sunderby Hospital, both Norrbotten Region, Sweden.

Acknowledgements
We thank Amanda Keineström Silvén, Sofia Måttson and Nazanin Shayeghi for their help with the validation of the clinical information, and Annika Essor, Anna Granberg, Annika Johansson, Ulrika Lundmark, Anna Nyberg, Eva Lång Ryhn for their help with assistance in conduct of the study.

Data availability
The data-sets generated and/or analysed during the current study are not publicly available due to lack of ethics committee permission and not having been part of the consent process. The structure of the data-set and the coding specification are available from the authors. Any other reasonable request will be raised with the regional ethics committee and healthcare provider.

9
subpopulations of bipolar patients in a German non-interventional study. BMC Psychiatry 2013; 13: 193.
22 McCreadle RG, McCormick M, Morrison DP. The impact of lithium in South- West Scotland. III. The discontinuation of lithium. Br J Psychiatry 1985; 146: 77–80.
23 Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predic-
tors. J Clin Psychiatry 2002; 63: 384–90.
24 Vieta E, Azorin J, Bauer M, Frangou S, Perugi G, Martinez G, et al. Psychiatrists’ per-
ceptions of potential reasons for non-partial adherence to medication: results of a survey in bipolar disorder from eight European countries. J Affect
Disord 2012; 143: 125–30.
25 Goodwin GM. Recurrence of mania after lithium withdrawal: implications for the use of lithium in the treatment of bipolar affective disorder. Br J Psychiatry 1994; 164: 149–52.
26 Kessing LV, Helmund G, Geddes JR, Goodwin GM, Andersen PK. Valproate vs. lith-
ium in the treatment of bipolar disorder in clinical practice: observational nation-
wide register-based cohort study. Br J Psychiatry 2011; 199: 57–63.
27 Kessing LV, Helmund G, Andersen PK. An observational nationwide register
based cohort study on lamotrigine versus lithium in bipolar disorder. J Psychopharmacology 2012; 26: 644–52.
28 Kessing LV, Bauer M, Nolen WA, Severus E, Goodwin GM, Geddes J. Effectiveness of maintenance therapy of lithium vs other mood stabilizers in monotherapy and in combinations: a systematic review of evidence from observational studies. Bipolar Disord 2018; 20: 419–31.
29 Garnham J, Munro A, Slaney C, Macdougall M, Passmore M, Duffy S, et al. Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord 2007; 104: 185–90.
30 Simhandl C, König B, Amann BL. A prospective 4-year naturalistic follow-up of treatment and outcome of 300 bipolar I and II patients. J Clin Psychiatry 2014; 75: 254–62.
31 Tondo L, Baldessarini RJ, Floris G. Long-term clinical effectiveness of lithium maintenance in types I and II bipolar disorders. Br J Psychiatry 2001; 178 (suppl 41): 184–90.
32 Soares-Weiser K, Vergel YB, Beynon S, Dunn G, Barbieri M, Duffy S, et al. A Systematic Review and Economic Model of the Clinical Effectiveness and Cost-Effectiveness of Interventions for Preventing Relapse in People with Bipolar Disorder. NIMH Health Technology Assessment programme: Executive Summaries. NIHJournals Library, 2007.
33 Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, et al. Lithium for pre-
vention of mood episodes in bipolar disorders: systematic review and meta-
analyses. Int J Bipolar Disord 2014; 2: 15.
34 Severus E, Bauer M, Geddes J. Efficacy and effectiveness of lithium in the long-
term treatment of bipolar disorders: an update 2018. Pharmacopsychiatry 2018, 52: 173–6.
35 Kane JM, Quittm K, Rifi K, Amos- Lorenzi JR, Nayak DD, Howard A. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry 1982; 39: 199–207.
36 Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine versus lith-
imonotherapy of bipolar II disorder: a randomized, double-blind, placebo-
substitution study. Am J Psychiatry 2010; 167: 792–800.
37 Hartong EG, Moleman P, Hoogduinn CA, Broekman TG, Nolen WA, Litcar Group. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipo-
lar patients. J Clin Psychiatry 2002; 64: 144–51.
38 Greil W, Ludwig-Mayerhofer W, Erazo N, Schöchlin C, Schmidt S, Engel R, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disor-
ders—a randomised study. J Affect Disord 1997; 43: 151–61.
39 Amsterdam JD, Loo J, Shults J. Efficacy and mood conversion rate during long-
term fluoxetine v. lithium monotherapy in rapid- and non-rapid-cycling bipolar II disorder. Br J Psychiatry 2013; 202: 301–6.
40 Amsterdam JD, Lorenzo-Luaces L, Soeler I, Li SG, Mao Ji, DeRubeis RJ. Safety and effectiveness of continuation antidepressant versus mood stabilizer mono-
therapy for relapse-prevention of bipolar II depression: a randomized, double-
blind, parallel-group, prospective study. J Affect Disord 2015; 185: 31–7.
41 Viktorin A, Lichtenstein P, Thase ME, Larsson H, Lundholm C, Magnusson PK, et al. The risk of switch tomania in patients with bipolar disorder during treat-
ment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry 2014; 171: 1067–73.
42 Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the man-
agement of patients with bipolar disorder. Bipolar Disord 2018; 20: 97–170.
43 Fountoulakis KN, Kuzniec H, Vieta E, Young A, Yatham L, Blier P, et al. The International College of Neuropsycho-pharmacology (CINP) treatment guide-
lines for Bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guide-
lines. Int J Neuropsychopharmacol 2017; 20: 180–95.
44 Takeshima M. Treating mixed mania/hypomania: a review and synthesis of the evidence. CNS Spectr 2017; 22: 177–85.
45 Plans L, Barrot C, Nieto E, Rios J, Schulze TG, Papiol S, et al. Association between completed suicide and bipolar disorder: a systematic review of the literature. J Affect Disord 2019; 242: 111–22.
46 Pallaskorpi S, Suominen K, Ketokivi M, Valtonen H, Arvilommi P, Mantere O, et al. Incidence and predictors of suicide attempts in bipolar I and II disorders: a 5-year follow-up study. Bipolar Disord 2017; 19: 13–22.
47 Tondo L, Vázquez GH, Pinna M, Vaccotto PA, Baldessarini RJ. Characteristics of depressive and bipolar disorder patients with mixed features. Acta Psychiatr Scand 2018; 138: 243–52.
48 Fiedorowicz JG, Persons JE, Assari S, Ostacher MJ, Zandi P, Wang PW, et al. Depressive symptoms carry an increased risk for suicidal ideation and behavior in bipolar disorder without any additional contribution of mixed symptoms. J Affect Disord 2019; 246: 775–82.
49 Tondo L, Baldessarini RJ. Antisuicidal effects in mood disorders: are they unique to lithium? Pharmacopsychiatry 2018; 51: 177–88.
50 Siskind D, Reddel T, MacCabe JH, Kisely S. The impact of clozapine initiation and cessation on psychiatric hospital admissions and bed days: a mirror image cohort study. Psychopharmacology (Berl) 2019; 236: 1931–5.